ETRA.US Electra Therapeutics, Inc. Common stock

Healthcare Biotechnology USA Stocks
8.84 USD
Close of Nov 14, 2026
6.87 15.50
Market cap
USD 555M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ETRA.US undervalued?

Graham number

The Graham number of Electra Therapeutics, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Electra Therapeutics, Inc. Common stock fundamental analysis

No fundamental analysis for Electra Therapeutics, Inc. Common stock yet.

Electra Therapeutics, Inc. Common stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Electra Therapeutics, Inc. Common stock

Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Maligna…

Full company profile